Immuron Limited

Contributing Author

Recent Articles by Immuron Limited

Nov-10	Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives IMRN GlobeNewswire
Oct-27	Immuron continued quarterly sales growth IMRN GlobeNewswire
Oct-22	Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference IMRN GlobeNewswire
Oct-13	Travelan Phase 2 Study Results Published IMRN GlobeNewswire
Sep-04	Immuron to launch PROIBS in the United States IMRN +62.16% GlobeNewswire
Aug-28	Immuron Reports FY26 Preliminary Results IMRN GlobeNewswire
Jul-20	Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar IMRN -6.61% GlobeNewswire
Jul-16	Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year IMRN -5.04% GlobeNewswire
Jul-06	Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy IMRN GlobeNewswire
Apr-17	Immuron Double Digit 3Q Sales Growth IMRN +13.35% GlobeNewswire
Mar-05	Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference IMRN GlobeNewswire
Feb-25	Immuron Reports HY26 Results and Strategic Reset IMRN +17.14% GlobeNewswire
Jan-19	Immuron Reports Continued Sales Growth IMRN GlobeNewswire
Dec-03	Immuron New U.S. Department of Defense Award & Clinical Trial Update IMRN -10.92% GlobeNewswire
Nov-05	Immuron IMM-529 IND approved by FDA IMRN -12.72% GlobeNewswire
Oct-31	Immuron Announces Clinical Trial Update IMRN -5.94% GlobeNewswire
Oct-13	Immuron Q1 FY26 YoY growth IMRN GlobeNewswire
Oct-08	Immuron Submits IMM-529 IND to FDA IMRN GlobeNewswire
Oct-02	Immuron Letter to Shareholders - Projects Update IMRN +7.86% GlobeNewswire
Aug-26	Immuron partners with InvestorHub IMRN GlobeNewswire
Jul-17	Immuron - FY25 global sales exceed projection, up 49% on prior year IMRN GlobeNewswire
May-30	Immuron Letter to Shareholders: Projects Update IMRN GlobeNewswire

Immuron Limited

Recent Articles by Immuron Limited

Upgrade your Finviz experience